{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:51:25Z","timestamp":1783115485712,"version":"3.54.6"},"reference-count":47,"publisher":"Georg Thieme Verlag KG","issue":"10","funder":[{"name":"National Health and Medical Research Council of Australia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There have been numerous and intriguing advancements in antithrombotic therapy for myocardial infarction since it was described in the earliest issues of Thrombosis and Haemostasis. In this article, we revisit historical breakthroughs and describe the four most challenging contemporary themes relating to antithrombotic therapy in myocardial infarction. In all four, the challenge is to find the best balance of reducing specific levels of ischaemic risks without increasing bleeding risk. The first is the question of the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). This includes discussion of monotherapy after a period of DAPT. The second relates to the role of genotype and phenotype-guided individualisation of antiplatelet therapy. There is emerging evidence for a role of pheno\/genotyping in identifying individuals at high risk for recurrent ischaemic events or in guiding the timing of cardiac surgery for patients on DAPT. The third addresses the increasing evidence for dual pathway inhibition, for example, with rivaroxaban in addition to aspirin in patients where high ischaemic and low bleeding risk is demonstrated. Finally the fourth highlights the challenge of the most appropriate combination of antiplatelet and anticoagulation therapy for patients with known atrial fibrillation after PCI. In most individuals, oral P2Y12 inhibitor therapy combined with a direct acting oral anticoagulant appears to be the best strategy based on the available evidence. Overall, the progress in antithrombotic therapy achieved over the last seven decades is remarkable, however, there are important issues to address and progress still to be made.<\/jats:p>","DOI":"10.1055\/s-0040-1714212","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T23:12:21Z","timestamp":1595632341000},"page":"1352-1356","source":"Crossref","is-referenced-by-count":10,"title":["Antithrombotic Therapy in Myocardial Infarction: Historic Perils and Current Challenges\u2014A 70-Year Journey"],"prefix":"10.1055","volume":"120","author":[{"given":"Dion","family":"Stub","sequence":"first","affiliation":[{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Cardiology, The Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himawan","family":"Fernando","sequence":"additional","affiliation":[{"name":"Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Cardiology, The Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"McFadyen","sequence":"additional","affiliation":[{"name":"Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Thrombosis and Haemostasis Unit, Department of Clinical Haematology, The Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jathushan","family":"Palasubramaniam","sequence":"additional","affiliation":[{"name":"Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Cardiology, The Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Cardiology, The Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[{"name":"Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlheinz","family":"Peter","sequence":"additional","affiliation":[{"name":"Atherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"Department of Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Cardiology, The Alfred Hospital, Melbourne, Victoria, Australia"},{"name":"Department of Immunology, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"ref1","first-page":"505","article-title":"The use of anticoagulants in cardiology","volume":"2","author":"P Formijne","year":"1958","journal-title":"Thromb Diath Haemorrh"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1055\/s-0040-1702920","article-title":"Platelet inhibition in acute coronary syndrome and percutaneous coronary intervention: insights from the past and present","volume":"120","author":"D A Gorog","year":"2020","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrcardio.2017.206","article-title":"Current and future antiplatelet therapies: emphasis on preserving haemostasis","volume":"15","author":"J D McFadyen","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.117.312012","article-title":"Novel antithrombotic drugs on the horizon: the ultimate promise to prevent clotting while avoiding bleeding","volume":"121","author":"J D McFadyen","year":"2017","journal-title":"Circ Res"},{"issue":"19","key":"ref5","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"M P Bonaca","year":"2015","journal-title":"N Engl J Med"},{"issue":"04","key":"ref6","first-page":"365","article-title":"Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"G Helft","year":"2016","journal-title":"Eur Heart J"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"C W Lee","year":"2014","journal-title":"Circulation"},{"issue":"23","key":"ref8","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"L Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"04","key":"ref9","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"J A Udell","year":"2016","journal-title":"Eur Heart J"},{"issue":"21","key":"ref10","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"R Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ahj.2019.02.015","article-title":"Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design","volume":"212","author":"C Kim","year":"2019","journal-title":"Am Heart J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"P Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1160\/TH17-02-0101","article-title":"Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents","volume":"117","author":"Y Harada","year":"2017","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jtcvs.2016.07.044","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"152","author":"G N Levine","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"J Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/ejcts\/ezx334","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"53","author":"M Valgimigli","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1055\/s-0038-1668546","article-title":"Platelet function or genetic testing for guiding de-escalation of anti-platelet therapy: the jury is still out","volume":"118","author":"D J Angiolillo","year":"2018","journal-title":"Thromb Haemost"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"D Sibbing","year":"2017","journal-title":"Lancet"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1055\/s-0038-1667337","article-title":"Genotype-phenotype association and impact on outcomes following guided de-escalation of anti-platelet treatment in acute coronary syndrome patients: The TROPICAL-ACS Genotyping Substudy","volume":"118","author":"L Gross","year":"2018","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"G N Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"M Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"ref23","first-page":"1583","article-title":"Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease?","volume":"19","author":"W Sumaya","year":"2019","journal-title":"Thromb Haemost"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1055\/s-0038-1636530","article-title":"Rivaroxaban: a new treatment paradigm in the setting of vascular protection?","volume":"118","author":"R Bauersachs","year":"2018","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1055\/s-0038-1668133","article-title":"Dual pathway inhibition with low-dose direct factor Xa inhibition after acute coronary syndromes-why is it not used in clinical practice?","volume":"118","author":"U Zeymer","year":"2018","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"J L Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"14","key":"ref27","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"J W Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"ref28","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"M P Bonaca","year":"2020","journal-title":"N Engl J Med"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"J H Alexander","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"ref30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"C P Cannon","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"ref31","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"R D Lopes","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"ref32","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"C M Gibson","year":"2016","journal-title":"N Engl J Med"},{"issue":"46","key":"ref33","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"G Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"P Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"C T January","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"ref36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/jci.insight.99329","article-title":"Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis","volume":"3","author":"D Hanjaya-Putra","year":"2018","journal-title":"JCI Insight"},{"key":"ref37","first-page":"989","article-title":"A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group","volume":"2","year":"1980","journal-title":"Lancet"},{"key":"ref38","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","year":"1988","journal-title":"Lancet"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/01.CIR.89.1.81","article-title":"Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group","volume":"89","author":"M Cohen","year":"1994","journal-title":"Circulation"},{"issue":"14","key":"ref40","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"issue":"17","key":"ref41","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"A Sch\u00f6mig","year":"1996","journal-title":"N Engl J Med"},{"issue":"07","key":"ref42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"M Cohen","year":"1997","journal-title":"N Engl J Med"},{"issue":"07","key":"ref43","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"S Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"20","key":"ref44","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"S D Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"ref45","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"G W Stone","year":"2008","journal-title":"N Engl J Med"},{"issue":"11","key":"ref46","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"S Yusuf","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"ref48","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"D L Bhatt","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1714212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T11:45:25Z","timestamp":1667562325000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1714212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,23]]},"published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1714212","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}